The DOI matches its Crossref record.
In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae
Open accessAbstract
BACKGROUND: Resistance to colistin is emerging in multidrug-resistant Gram-negative bacteria and no solid pharmacodynamic data are available for colistin against Klebsiella pneumoniae. METHODS: Twenty-one multidrug-resistant clinical K. pneumoniae isolates from 16 different clinical sites worldwide were employed. The genetic relatedness of these isolates was examined with PFGE. In vitro pharmacodynamic properties of colistin (sulphate) were investigated by studying the MICs, mutation prevention concentrations, time-kill kinetics, population analysis profiles and the post-antibiotic effect (PAE). Time-kill was studied with three clinical isolates plus ATCC 13883 at concentrations ranging from 0.5 to 64x MIC. The PAE was examined after 20 min of exposure of these isolates. RESULTS: The 22 isolates belonged to 18 different PFGE groups. For susceptible isolates, colistin MICs ranged from 0.125 to 1 mg/L. Six isolates were colistin-resistant with MICs of >/=32 mg/L. Colistin heteroresistance was observed in 15 of 16 isolates considered colistin-susceptible based on MICs. For susceptible isolates, colistin showed extremely rapid killing; however, regrowth was observed as early as 2 h after treatment and substantial regrowth at 24 h even at concentrations up to 64x MIC for some isolates. Colistin exhibited no or very modest PAE against the isolates tested. CONCLUSIONS: The data suggest that monotherapy with colistin methanesulfonate, the parenteral form of colistin, and long dosage intervals may be problematic for the treatment of infections caused by multidrug-resistant K. pneumoniae, particularly for colistin-heteroresistant strains. Further investigation on combination therapy of colistin with other antibiotics is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Poirel, L., Jayol, A., & Nordmann, P. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-16 · Cited by 1,447
Structure−Activity Relationships of Polymyxin Antibiotics
Velkov, T., Thompson, P. E., Nation, R. L., & Li, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900999h · Cited by 780
Self-citationColistin: an update on the antibiotic of the 21st century
Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M., & Rolain, J.-M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.78 · Cited by 581
Pharmacokinetics and Pharmacodynamics of Antibacterial Agents
Levison, M. E., & Levison, J. H. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.008 · Cited by 557
Mechanisms and clinical relevance of bacterial heteroresistance
Andersson, D. I., Nicoloff, H., & Hjort, K. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0218-1 · Cited by 513
Pharmacology of Polymyxins: New Insights into an ‘Old‘ Class of Antibiotics
Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E., & Li, J. (2013) · Future Microbiology · doi:10.2217/fmb.13.39 · Cited by 452
Self-citationResurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
Lim, L. M., Ly, N., Anderson, D., Yang, J. C., Macander, L., Jarkowski, A., Forrest, A., Bulitta, J. B., & Tsuji, B. T. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.12.1279 · Cited by 444
Nation, R. L., & Li, J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332e672 · Cited by 443
Self-citation“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Rescuing the Last-Line Polymyxins: Achievements and Challenges
Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. (., & Li, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000020 · Cited by 421
Self-citationResistance to polymyxins in Gram-negative organisms
Jeannot, K., Bolard, A., & Plésiat, P. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.11.029 · Cited by 402
Nicoloff, H., Hjort, K., Levin, B. R., & Andersson, D. I. (2019) · Nature Microbiology · doi:10.1038/s41564-018-0342-0 · Cited by 401
Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
Nation, R. L., Velkov, T., & Li, J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu213 · Cited by 310
Self-citationMultidrug-Resistant Gram-Negative Infections: What are the Treatment Options?
Giamarellou, H., & Poulakou, G. (2009) · Drugs · doi:10.2165/11315690-000000000-00000 · Cited by 288
Current Update on Intrinsic and Acquired Colistin Resistance Mechanisms in Bacteria
Gogry, F. A., Siddiqui, M. T., Sultan, I., & Haq, Q. M. R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.677720 · Cited by 265
Antibacterial Mechanisms of Polymyxin and Bacterial Resistance
Yu, Z., Qin, W., Lin, J., Fang, S., & Qiu, J. (2015) · BioMed Research International · doi:10.1155/2015/679109 · Cited by 263
Colistin: new lessons on an old antibiotic
Yahav, D., Farbman, L., Leibovici, L., & Paul, M. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03734.x · Cited by 259
Wang, Y., Ma, X., Zhao, L., He, Y., Yu, W., Fu, S., Ni, W., & Gao, Z. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.868991 · Cited by 27
Treatment of Acinetobacter baumannii severe infections
Reina, R., León-Moya, C., & Garnacho-Montero, J. (2022) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2022.08.007 · Cited by 22
Weng, Y., Wang, T., Huang, B., Yu, H., Jia, W., Shan, B., Qu, F., Tang, Y., Chen, L., & Du, H. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02218-22 · Cited by 20
Rajakani, S. G., Xavier, B. B., Sey, A., Mariem, E. B., Lammens, C., Goossens, H., Glupczynski, Y., & Malhotra-Kumar, S. (2023) · Genes · doi:10.3390/genes14071426 · Cited by 17
Metadata
- Authors
- Poudyal, A., Howden, B. P., Bell, J. M., Gao, W., Owen, R. J., Turnidge, J. D., Nation, R. L., & Li, J.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-09-10
- Volume
- 62
- Issue
- 6
- Pages
- 1311-1318
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2163732007
- Cited by
- 185
- References
- 0
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.